COPENHAGEN, Denmark (15 September, 2016)
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Jesper Bramming has joined Symphogen as its new Chief Financial Officer, filling the position vacated by Martin Olin, M.Sc., EMBA, who was promoted to Chief Executive Officer and member of the Board of Directors.
Jesper Bramming comes to Symphogen from the CMC Biologics Group where he was Chief Financial Officer and a member of the Group Management Team. His responsibilities included financial accounting and reporting, legal and IT. Prior to CMC Biologics, Bramming was Executive Vice President and Chief Financial Officer with Nets Holding A/S . Prior to that, for sixteen years, he held financial management level positions within the A.P: Møller-Maersk Group and was Chief Financial Officer of Svitzer A/S. Prior to these assignments, Bramming held a number of senior positions in banking and investment management in leading European firms. He holds Board seats as Chairman of both Menu A/S Scandinavia Living A/S and Rejsekort A/S, and is a director of Danske Invest Management. He holds a Master of Economics from the University of Copenhagen, and is an alumni of Columbia University's Senior Executive Management Program. He is also a Chartered Financial Analyst.
Chief Executive Officer, Martin Olin, commented: "Jesper brings to Symphogen his extensive experience at one of the top international companies in Denmark, and more recently, expertise in the healthcare sector from CMC Biologics, now one of the world's leading contract manufacturing businesses. His success in both multi-national finance, healthcare experience and investment banking background uniquely positions him to be part of Symphogen as we mature our proprietary portfolio and explore strategic opportunities."
About Symphogen A/S
Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use in oncology. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product. The company has collaborations for the development of antibody therapeutics in the infectious disease area with Genentech, and in immuno-oncology with Shire. Symphogen employs 125 people, has offices in Denmark and New Jersey, US and its investors include Essex Woodlands Health Ventures, Novo A/S, PKA, Sunstone Capital, Gilde Healthcare Partners, Danica Pension, Takeda Ventures, Inc., and Genentech. For more information, please see www.symphogen.com
For additional information, please contact:
Chief Executive Officer, Mr. Martin Olin
Phone: +45 40 21 85 32